Publications by authors named "Nathan A Lau"
Article Synopsis
- Castration-resistant prostate cancer (CRPC) includes various subtypes, notably androgen receptor-active prostate cancer (ARPC) and neuroendocrine prostate cancer (NEPC), which can exist simultaneously in patients, complicating treatment strategies.
- Current therapies lack effectiveness across these different CRPC subtypes, prompting research on a new combined treatment approach.
- The study found that fimepinostat, a dual inhibitor of histone deacetylase (HDAC) and PI3K/AKT, significantly inhibits tumor growth in both ARPC and NEPC models, showing better results when both pathways are targeted together rather than separately.
The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC.
View Article and Find Full Text PDF